Stalled Promises and Growing Discontent
Eight months after Environmental Protection Agency (EPA) Administrator Lee Zeldin pledged to release a formal agenda for the “Make America Healthy Again” (MAHA) movement, activists are expressing deep frustration. The document, which was intended to outline specific federal protections against harmful chemicals and chronic health risks, has failed to materialize. EPA spokespeople now characterize MAHA as an “ongoing effort” rather than a singular policy document, a pivot that critics view as a tactical retreat from accountability.
The tension stems from a December 2025 commitment made by Zeldin following intense pressure, including a petition from advocates demanding his resignation. Now, as the movement faces a series of regulatory setbacks, activists are signaling that their support for the Trump administration in the upcoming midterm elections is no longer guaranteed.
Regulatory Reversals and Industry Influence
The friction is compounded by specific policy shifts within the agency. In late June, the EPA reversed course on testing for microplastics and pharmaceuticals in drinking water, despite having previously highlighted these as priority contaminants. Administrator Zeldin defended the move, citing ongoing technological limitations, but former agency officials have characterized the change as a “bait-and-switch” that undermines public health goals.
Critics point to a broader pattern of industry-aligned policymaking within the current EPA. Several key positions are held by former lobbyists, including those from the chemical and agricultural sectors. The agency’s recent decision to continue the use of the herbicide dicamba—despite cancer-related concerns—has further deepened the divide between MAHA supporters and the agency’s leadership.
Electoral Stakes
The MAHA movement, which played a pivotal role in the recent presidential cycle, is now shifting its strategy. Activists such as Kelly Ryerson and organizations like Moms Across America are emphasizing that they are prepared to prioritize health policy over party loyalty in November. As the EPA continues its aggressive deregulatory path—including the rollback of climate health findings and research funding—the political fallout may prove significant for the administration’s coalition.